The TCR Therapy Market focuses on adoptive T‑cell therapies engineered to express specific T‑cell receptors (TCRs) that recognize peptide antigens presented on tumor cells’ HLA molecules. Unlike many CAR‑T therapies that target surface proteins, TCR therapies can access a broader repertoire of intracellular antigens, including neoantigens and cancer‑testis antigens, expanding the...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek